Cargando…

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study

Novel antidiabetic drugs have the ability to produce anti-inflammatory effects regardless of their glucose-lowering action. For this reason, these molecules (including GLP-1 RAs and DPP-4is) were hypothesized to be effective against COVID-19, which is characterized by cytokines hyperactivity and mul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greco, Salvatore, Monda, Vincenzo M., Valpiani, Giorgia, Napoli, Nicola, Crespini, Carlo, Pieraccini, Fabio, Marra, Anna, Passaro, Angelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452157/ https://www.ncbi.nlm.nih.gov/pubmed/37626788 http://dx.doi.org/10.3390/biomedicines11082292

Ejemplares similares

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy
por: Monda, Vincenzo M., et al.
Publicado: (2023)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential
por: Mustafa, Omar G., et al.
Publicado: (2019)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
por: Pan, Xiaohui, et al.
Publicado: (2020)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4
por: Wu, Luting, et al.
Publicado: (2022)

Inhibition of DPP-IV Activity and Stimulation of GLP-1 Release by Gastrointestinally Digested Black Soldier Fly Prepupae
por: Luparelli, Anna Valentina, et al.
Publicado: (2023)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

LncRNA-OIS1 regulates DPP4 activation to modulate senescence induced by RAS
por: Li, Li, et al.
Publicado: (2018)

ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?
por: Monda, Vincenzo M., et al.
Publicado: (2020)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2016)

Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study
por: Pérez-Durillo, Francisco Tomás, et al.
Publicado: (2018)

DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
por: Kim, Seung Jung, et al.
Publicado: (2019)

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
por: Han, Eugene, et al.
Publicado: (2016)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis
por: Wang, Tiantian, et al.
Publicado: (2021)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
por: Rhee, Sang Youl, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
por: Imam, Ahmad, et al.
Publicado: (2023)

The Effects of Aerobic Exercises and 25(OH) D Supplementation on GLP1 and DPP4 Level in Type II Diabetic Patients
por: Rahimi, Naser, et al.
Publicado: (2017)

DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity
por: Böhm, Anja, et al.
Publicado: (2017)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Effects of Sambiloto (Andrographis paniculata) on GLP-1 and DPP-4 Concentrations between Normal and Prediabetic Subjects: A Crossover Study
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
por: Geloneze, Bruno, et al.
Publicado: (2017)

Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
por: Hu, Ying, et al.
Publicado: (2022)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice
por: Romera, Irene, et al.
Publicado: (2023)

Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? – GLP-1 might play one too
por: Morin, Nathaniel
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96c27faa7b5qan8cdu5f0c9q8q